Intellia Soars as Data for Gene Editing Candidate in Hereditary Angioedema is Revealed
June 14, 2023
🌥️Trending News
Intellia Therapeutics ($NASDAQ:NTLA), a leading biopharmaceutical company specializing in the development of gene editing therapies, recently saw its stocks soar after the acquisition of data for its gene editing candidate in hereditary angioedema. Over the past few months, Intellia has been working on a new gene therapy to treat hereditary angioedema, a rare genetic disorder that causes recurrent episodes of swelling. Their efforts have largely been successful, leading to the development of several revolutionary treatments for rare genetic disorders. These treatments have garnered much attention from both within the pharmaceutical industry and the investment community. As a result, Intellia’s stock has been steadily rising over the past few years.
This news has allowed investors to believe that the drug is likely to be successful as a treatment option for this disorder, which has led to the stock’s rapid rise. This news has greatly bolstered investor confidence in the company, leading many to believe that their revolutionary treatments will be successful. As such, it is likely that Intellia’s stock will continue to rise in the near future.
Share Price
The stock opened at $44.2 and closed at $43.6, up by 0.9% from prior closing price of 43.2. These findings prompted a substantial rally in the stock, as investors become increasingly confident about the potential of INTELLIA’s gene-editing platform. This is promising news for the company, as their therapy candidate has the potential to improve the quality of life of many affected by HAE. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Intellia Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 53.48 | -430.44 | -780.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Intellia Therapeutics. More…
| Operations | Investing | Financing |
| -333.29 | 160.31 | 582.96 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Intellia Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.42k | 227.05 | 14.03 |
Key Ratios Snapshot
Some of the financial key ratios for Intellia Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 5.5% | – | -796.4% |
| FCF Margin | ROE | ROA |
| -732.4% | -21.5% | -18.8% |
Analysis
At GoodWhale, we have analyzed the financials of INTELLIA THERAPEUTICS and have determined that it is a high risk investment. Our Risk Rating feature provides insight into the financial and business aspects of the company and has identified three risk warnings in the balance sheet, cashflow statement, and non-financial metrics. These warnings should be taken into serious consideration before investing. If you’re interested in finding out more about INTELLIA THERAPEUTICS’s risk profile, register with us and we’ll provide you with a comprehensive assessment of the company’s financial health. We’ll provide insights into the health of its balance sheet, cashflow statement, and non-financial metrics so you can make an informed decision about investing. More…
Peers
The company was founded in 2014 and is based in Cambridge, Massachusetts. Intellia has developed a platform that can be used to edit genes in a variety of cells and tissues. The company is also working on developing CRISPR-based treatments for diseases such as cancer and HIV. Intellia’s main competitors are CRISPR Therapeutics AG, Regeneron Pharmaceuticals Inc, and Editas Medicine Inc.
– CRISPR Therapeutics AG ($NASDAQ:CRSP)
Crispr Therapeutics AG is a biopharmaceutical company that focuses on the development of CRISPR/Cas9-based therapeutics for serious diseases. The company’s market cap as of 2022 is 4.28B and its ROE is -18.27%. Crispr Therapeutics AG was founded in 2013 and is headquartered in Zug, Switzerland.
– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)
Regeneron Pharmaceuticals Inc is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s products include EYLEA, Praluent, Dupixent, Libtayo, and Kevzara. As of 2021, the company had a market cap of $80.72 billion and a return on equity of 19.7%. Regeneron was founded in 1988 and is headquartered in Tarrytown, New York.
– Editas Medicine Inc ($NASDAQ:EDIT)
Editas Medicine Inc is a genome editing company based in Cambridge, Massachusetts. The company uses a technology called CRISPR to edit genes in order to treat genetic diseases. As of 2022, Editas Medicine Inc has a market cap of 886.02M and a Return on Equity of -23.75%. The company’s focus on genome editing makes it a leader in the field, and its market cap and ROE reflect this.
Summary
Intellia’s pipeline consists of four clinical-stage programs, emphasizing treatments for genetic diseases such as hereditary angioedema, beta thalassemia & sickle cell disease. Key risk factors to consider when investing in Intellia include the competitive landscape of gene editing, the company’s dependence on external funding, and regulatory approval – all of which could affect the timing and success of Intellia’s potential curative therapies.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
